

Degenerative Disc Disease Treatment Volume is rising at a CAGR of 5.5% from 2023 to 2032

PORTLAND, IL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- [Degenerative Disc Disease Treatment Market](#)

According to the report, the global degenerative disc disease treatment market generated \$28 billion in 2022, and is anticipated to generate \$46.2 billion by 2032, rising at a CAGR of 5.5% from 2023 to 2032.

Request Sample of the Report on- <https://www.alliedmarketresearch.com/request-sample/A269439>

Prime Determinants of Growth

The increasing prevalence of degenerative disc disease (DDD) among the aging population, growing awareness about spine health and available treatment options, and the innovations in imaging technology & surgical tools are the factors expected to drive the growth of the global degenerative disc disease treatment market in the forecast period from 2023 to 2032. However, the increasing availability of various alternative treatment and pain management methods for degenerative disc disease may restrict market growth in the coming future. Contrarily, technological innovations in medical technology, such as robotics, 3D printing, and advanced imaging techniques is expected to offer remunerative opportunities for the degenerative disc disease treatment market expansion during the forecast period.

Segments Overview

Drugs: NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Sub-segment to be the Most Dominant by 2032

The NSAIDs (non-steroid anti-inflammatory drugs) sub-segment accounted for the largest global degenerative disc disease treatment market share of 35.1% in 2022 and is expected to hold major share and rise at a CAGR of 6.2% during the forecast period. NSAIDs' effectiveness in reducing pain, inflammation, and fever, their over-the-counter availability, and their ability to address multiple symptoms simultaneously drive their widespread use for various conditions like arthritis and minor ailments, which is driving the sub-segment's growth. In addition, NSAIDs are a popular choice for self-medication.

Treatment Type: Physical Therapy Sub-segment to Flourish Immensely During the Forecast Period

The physical therapy sub-segment held the largest market share of 30.6% in 2022 and is predicted to grow at the highest CAGR of 6.5% during the forecast period. This dominant growth can be attributed to physical therapy's non-invasive nature, its proven effectiveness in reducing pain and improving mobility, and its use of therapeutic exercises and modalities like ultrasound and electrical stimulation make it a preferred treatment for degenerative disc disease. This approach appeals to both patients and healthcare providers seeking conservative management options.

Route of Administration: Oral Sub-segment to Witness Dominant Growth by 2032

The oral control sub-segment accounted for the largest global degenerative disc disease treatment market share of 65.5% in 2022 and is expected to be most dominant by growing at the highest CAGR of 6.0% during the forecast period. This is mainly because oral medications for degenerative disc disease, such as NSAIDs, muscle relaxants, and analgesics, offer convenience and ease of administration, making them preferred by patients and healthcare providers. Their availability over-the-counter or with a prescription ensures accessibility in hospitals, clinics, and pharmacies, providing flexibility in managing the condition.

End Use: Hospitals Sub-segment to Thrive Significantly During the Forecast Period

The hospitals sub-segment held the largest market share of 45.5% in 2022 and is predicted to grow at the highest CAGR of 6.2% during the forecast period. This is mainly because specialized departments in hospitals dedicated to orthopedics, neurology, or spine care, equipped with advanced diagnostic tools and treatment modalities enable comprehensive care for patients with complex spinal conditions. This infrastructure drives hospitals to become preferred destinations for specialized treatment of degenerative disc disease.

For Purchase Enquiry- <https://www.alliedmarketresearch.com/purchase-enquiry/A269439>

Region: North America Market to Hold Major Share by 2032

The North America degenerative disc disease treatment market accounted for the largest share of 34.1% in 2022 and is predicted to continue to hold major share by 2032. This is mainly due to the advancements in medical technology, rising healthcare expenditure, and increased patient awareness. Besides, the increasing prevalence of degenerative disc disease (DDD) attributed to aging populations and sedentary lifestyles is another factor driving the regional market growth.

Leading Players in the Degenerative Disc Disease Treatment Market:

Eli Lilly and Company
Spine BioPharma
Novartis AG
FibroGenesis
Ferring B.V.
Pfizer Inc.
AstraZeneca Plc
Medtronic plc
DiscGenics, Inc.
Braun Melsungen AG

□□□□□ □□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+ +1 800-792-5285

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/849883228>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.